CelLBxHealthFRA:DWV Gross Margin % is 65.93% as of Dec. 2025, which is 6% below its 10-year median of 70.28. The stock has 5 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, CelLBxHealth ranks better than 63.92% on this metric.
CelLBxHealth PLC gross margin has been in long-term decline. The average rate of decline per year is -3.9%.
The historical rank and industry rank for CelLBxHealth's Gross Margin % or its related term are showing as below:
FRA:DWV'
s Gross Margin % Range Over the Past 10 Years
Min: 58.89 Med: 70.28 Max: 78.35
Current: 61.58
During the past 13 years, the highestGross Margin % of CelLBxHealth was 78.35%. The lowest was 58.89%. And the median was 70.28%.
FRA:DWV's Gross Margin % is ranked better than 63.92% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: 50.45
vs FRA:DWV: 61.58
CelLBxHealth had a gross margin of 65.93% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for CelLBxHealth was -3.90% per year.
CelLBxHealth (FRA:DWV) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
CelLBxHealth had a gross margin of 65.93% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
CelLBxHealth Gross Margin % Related Terms
CelLBxHealth Gross Margin % Historical Data
* Premium members only.
The historical data trend for CelLBxHealth's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:DWV vs TMO, DHR, IDXX: Gross Margin % Comparison
For the Diagnostics & Research subindustry, CelLBxHealth's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CelLBxHealth Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, CelLBxHealth's Gross Margin % distribution charts can be found below:
* The bar in red indicates where CelLBxHealth's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
CelLBxHealth (FRA:DWV) has a Gross Margin % of 65.93% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on CelLBxHealth and its competitors. This is near median its historical median of 70.28. Over the past decade, CelLBxHealth's Gross Margin % has ranged from 58.89 to 78.35. According to the industry distribution chart, CelLBxHealth ranks #70 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 36.1%.
Is CelLBxHealth's Gross Margin % too high?
CelLBxHealth's current Gross Margin % of 65.93% is near median its 10-year median of 70.28. Over the past 10 years, this metric has ranged from a low of 58.89 to a high of 78.35. The Medical Diagnostics & Research industry median Gross Margin % is 50.45. CelLBxHealth's value of 65.93% is 30.7% above this industry median. Based on the distribution chart, CelLBxHealth ranks #70 out of 194 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint.
How does CelLBxHealth's Gross Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, CelLBxHealth ranks #70 out of 194 companies for Gross Margin %. This puts CelLBxHealth in the upper half of its industry. The industry median Gross Margin % is 50.45. CelLBxHealth's value of 65.93% is 30.7% above this benchmark. Historically, CelLBxHealth's own Gross Margin % has ranged from 58.89 to 78.35 over the past decade. While the company's 10-year median is 70.28 vs. the industry median of 50.45, CelLBxHealth has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 50.45, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CelLBxHealth's current Gross Margin % of 65.93% is 30.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on CelLBxHealth and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 50.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CelLBxHealth's current Gross Margin % is 65.93%, which is near median its own 10-year median of 70.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CelLBxHealth stock overvalued right now?
Based on GuruFocus' analysis, CelLBxHealth (FRA:DWV) is currently considered Possible Value Trap. The stock's GF Value™ is €0.07, compared to a current price of €0.02 — trading 75.7% below its estimated fair value. The current Gross Margin % is 65.93%, which is near median its 10-year median of 70.28 and 30.7% above the Medical Diagnostics & Research industry median of 50.45. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For CelLBxHealth (FRA:DWV), the current Gross Margin % is 65.93% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CelLBxHealth PLC is active in the healthcare sector in the United Kingdom. The Company's principal trading activity is undertaken in relation to the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy that is non-invasive cancer diagnostics. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which the majority of its revenue is generated from Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:DWV has been successfully added to your 